Tirzepatide vs. Ozempic: Key Differences Explained

Tirzepatide vs. Ozempic comes up constantly in weight loss conversations, but the comparison is trickier than it looks — because Ozempic isn’t actually FDA-approved for weight loss at all. It’s a type 2 diabetes medication that some people also lose weight on, which is a meaningfully different starting point than tirzepatide’s dedicated weight-loss approval under the brand name Zepbound. Here’s what that difference actually means, and where compounded options fit into the picture.

Key Takeaways

• Ozempic is FDA-approved for type 2 diabetes, not weight loss. Wegovy is the FDA-approved weight-loss brand of the same active ingredient, semaglutide, at a higher dose.
• Ozempic’s approved dose tops out at 2 mg weekly; Wegovy goes up to 2.4 mg (and higher with Wegovy HD).
• Tirzepatide activates two hormone receptors instead of one and has shown stronger average weight loss in its own obesity trials than semaglutide has in its own.
• Using Ozempic specifically for weight loss is an off-label use, at a lower dose than semaglutide’s weight-loss-optimized version.
• Compounded semaglutide and tirzepatide are a separate category from all four brand-name products discussed here — they are not FDA-approved formulations, and understanding that distinction matters before you start treatment.

What Is Ozempic, Exactly?

Ozempic is the brand name for semaglutide, FDA-approved specifically for type 2 diabetes management and for reducing cardiovascular risk in certain patients. It works as a GLP-1 receptor agonist — mimicking a natural gut hormone that slows digestion, signals fullness to the brain, and helps the pancreas release insulin appropriately.

The same active ingredient is also sold under the brand name Wegovy, dosed higher and FDA-approved specifically for chronic weight management. Ozempic’s maximum approved dose is 2 mg weekly; Wegovy’s goes up to 2.4 mg, with a higher “Wegovy HD” (7.2 mg) option approved more recently. That dose gap is the main reason weight loss on Ozempic tends to run more modest than what’s reported in Wegovy’s own clinical trials — people using Ozempic are, by definition, on a lower dose of the same drug than the one actually studied for weight loss.

What Is Tirzepatide?

Tirzepatide activates two hormone receptors instead of one — both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). It’s sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, splitting by indication the same way semaglutide splits into Ozempic and Wegovy. The added GIP pathway is associated with stronger appetite control and greater average weight loss in tirzepatide’s own clinical trials compared with GLP-1-only medications.

Tirzepatide vs. Ozempic: Side-by-Side

Does Tirzepatide Lead to More Weight Loss Than Ozempic?

This is where precision matters. In the SURMOUNT-1 trial, tirzepatide at the highest studied dose (15 mg) produced an average weight loss of 20.9% of body weight at 72 weeks, compared with 3.1% for placebo. That result comes from Zepbound-equivalent dosing — not a head-to-head trial against Ozempic.

Ozempic itself was studied at its approved 2 mg dose in the SUSTAIN FORTE trial, in adults with type 2 diabetes rather than a general obesity population, where the 2 mg dose produced an average of 6.9 kg of weight loss over 40 weeks versus 6.0 kg on the 1 mg dose. That’s a different population, different dose, different duration, and a different endpoint (kilograms, not percentage of body weight) than SURMOUNT-1, so the two numbers can’t be honestly converted into a clean side-by-side percentage. What can be said accurately: Ozempic’s approved dose is meaningfully lower than the dose semaglutide is actually optimized for, and tirzepatide’s own weight-loss trials have outperformed semaglutide’s, dose for dose, in the SURMOUNT-5 head-to-head trial against Wegovy — worth a read if you want the fair, apples-to-apples version of this comparison.

Why Do People Confuse Ozempic With Wegovy?

Ozempic became a household name faster than Wegovy did, even though Wegovy is the version actually built and dosed for weight loss. Ozempic launched in 2017 for diabetes, four years before Wegovy’s 2021 approval, and a wave of off-label prescribing and media coverage cemented “Ozempic” as generic shorthand for GLP-1 weight loss medications broadly — the same way “Kleenex” became shorthand for tissues. That’s exactly why so many people ask “tirzepatide vs. Ozempic” when what they actually want to know is how tirzepatide compares to semaglutide dosed for weight loss, which is Wegovy’s job, not Ozempic’s.

This matters practically: asking a provider for “Ozempic” by name, rather than describing the goal of weight loss, can result in a lower, diabetes-calibrated dose than what’s actually indicated for weight management.

Where Compounded Semaglutide and Tirzepatide Fit In

Everything above — Ozempic, Wegovy, Mounjaro, Zepbound — refers to brand-name, FDA-approved formulations manufactured by their respective drug makers. Compounded semaglutide and tirzepatide are a different category entirely: versions of the same active ingredients prepared by a state-licensed compounding pharmacy based on an individual prescription, rather than manufactured and FDA-approved as a finished brand-name drug.

That distinction isn’t a technicality. Compounded medications are not FDA-approved — they have not been evaluated by the FDA for safety, effectiveness, or quality the way Ozempic, Wegovy, Mounjaro, and Zepbound have been. Compounding is a legal, regulated practice used when a licensed pharmacy prepares a medication tailored to a patient’s needs, typically under state pharmacy board oversight rather than FDA drug approval. If cost or access is steering you away from the brand-name options discussed above, a compounded formulation is worth understanding on its own terms — not as an equivalent or substitute assumed to carry the same FDA approval status.

Administration and Getting Started

Both Ozempic and tirzepatide-based medications are given as once-weekly subcutaneous injections, typically in the abdomen, thigh, or upper arm, using a gradual dose-escalation schedule that starts low and increases every few weeks to limit side effects. Neither requires daily dosing or timing around meals. If you’re new to injectable treatment, our guide to the ideal injection sites for tirzepatide covers technique and site rotation that applies broadly to GLP-1 and GIP/GLP-1 injections.

Getting started with any of these medications — brand-name or compounded — should begin with a medical evaluation, not a decision based on which name is most familiar. A provider can review your diagnosis, medical history, and goals to recommend an appropriate option and dose.

Side Effects

Both medications cause similar categories of side effects, since both slow digestion as part of how they work: nausea, vomiting, diarrhea, constipation, and stomach discomfort, most noticeable early in treatment or after a dose increase. For a detailed, sourced breakdown, see our full guides on what to expect from tirzepatide’s side effect profile and semaglutide’s side effect profile, the active ingredient in Ozempic.

Cost and Insurance Coverage

This is often the deciding factor in practice, more than the clinical data. Ozempic frequently has better insurance coverage than Zepbound or Wegovy, specifically because it carries an FDA-approved diabetes indication — many insurance plans cover diabetes medications more readily than weight-loss medications, even when the underlying drug is identical. This is a major reason some patients end up on Ozempic for weight loss despite Wegovy being the version actually studied and approved for that purpose: it’s what their insurance will pay for.

If you don’t have a diabetes diagnosis, this coverage gap is worth discussing directly with your provider and insurer. It’s also the reason compounded options exist in the market at all — as an alternative path for patients who don’t have access to affordable brand-name coverage, prepared by a licensed pharmacy under a valid prescription rather than sold as an FDA-approved product.

Which Should You Choose?

If your primary goal is weight loss and you don’t have type 2 diabetes, the FDA-approved, dose-appropriate brand-name options are Zepbound (tirzepatide) or Wegovy (semaglutide) — not Ozempic, which wasn’t studied or dosed for this purpose. If you have type 2 diabetes and your insurance covers Ozempic, it can be a reasonable starting point that also supports some weight loss, but it’s worth an honest conversation with your provider about whether Mounjaro, Wegovy, or Zepbound better matches your goals.

If cost or insurance access rules out the brand-name path, a compounded formulation prepared by a licensed pharmacy is a separate option to discuss with a provider — understanding clearly that it is not the FDA-approved product, and choosing it on that basis rather than assuming equivalence. The right choice depends on your diagnosis, insurance situation, side effect tolerance, budget, and how much weight loss you’re aiming for — not brand recognition.

Frequently Asked Questions

Is Ozempic the same as tirzepatide?
No. Ozempic is semaglutide, a GLP-1-only medication. Tirzepatide is a different molecule that activates both GLP-1 and GIP receptors, sold as Mounjaro (diabetes) or Zepbound (weight loss).

Is Ozempic approved for weight loss?
No. Ozempic is FDA-approved for type 2 diabetes. Wegovy is the FDA-approved weight-loss brand of the same drug, dosed higher than Ozempic.

Can I use Ozempic for weight loss anyway?
Some providers prescribe it off-label for weight loss, but it’s dosed lower than Wegovy, the version studied and approved for that purpose, so results are typically more modest.

Which causes more weight loss, tirzepatide or Ozempic?
Tirzepatide’s own obesity trials (SURMOUNT-1) show stronger average results than semaglutide at its approved weight-loss dose (Wegovy). Ozempic wasn’t studied at a weight-loss-optimized dose, so a direct comparison isn’t scientifically clean — but less weight loss on Ozempic than on Wegovy or tirzepatide is a reasonable expectation.

Is tirzepatide more expensive than Ozempic?
It depends heavily on insurance. Ozempic often has broader coverage due to its diabetes indication, while tirzepatide’s weight-loss version (Zepbound) can be harder to get covered without a diabetes diagnosis, regardless of list price.

Is compounded semaglutide or tirzepatide the same as Ozempic, Wegovy, Mounjaro, or Zepbound?
No. Compounded versions are prepared by a licensed compounding pharmacy under an individual prescription and are not FDA-approved, unlike the four brand-name products discussed in this article.

Why do so many people say “Ozempic” when they mean any GLP-1 weight loss medication?
Ozempic reached the market and public awareness years before Wegovy, so its brand name became a catch-all term the way “Kleenex” or “Google” did for their categories. Asking for “Ozempic” by name rather than describing your actual goal can result in a diabetes-calibrated dose rather than a weight-loss-optimized one.

The Bottom Line

Comparing tirzepatide to Ozempic directly isn’t quite the same question as comparing tirzepatide to semaglutide broadly — Ozempic is capped at a lower dose than the weight-loss-optimized version of the same drug (Wegovy), which limits how directly the two can be measured against each other. If you want the most accurate medication comparison for weight loss specifically, our semaglutide vs. tirzepatide guide compares the two at their actual weight-loss doses. If cost or coverage is steering you toward compounded options instead of a brand-name product, a consultation is the right next step to understand what’s appropriate for your situation.

This article is for general education and is not a substitute for personalized medical advice. Talk to a healthcare provider about which medication, formulation, and dose is appropriate for your individual diagnosis, health history, and goals.

Sources

• Ozempic (semaglutide) FDA Prescribing Information
• Wegovy (semaglutide) FDA Prescribing Information
• Zepbound (tirzepatide) FDA Prescribing Information
• Jastreboff et al., “Tirzepatide Once Weekly for the Treatment of Obesity” (SURMOUNT-1), NEJM
• Frías et al., “Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg” (SUSTAIN FORTE), Lancet Diabetes & Endocrinology

Medica Weight Loss offers compounded semaglutide and tirzepatide, prepared by a state-licensed compounding pharmacy based on a valid individual prescription. These compounded medications are not FDA-approved — they have not been evaluated by the FDA for safety, effectiveness, or quality. Any reference to FDA-approved medications elsewhere in this article refers solely to brand-name formulations such as Wegovy®, Ozempic®, Zepbound®, and Mounjaro®, which are not what Medica Weight Loss dispenses.